Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

Stock Information for Selecta Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Selecta Biosciences Inc.

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
Iridex Reports Third Quarter 2025 Financial Results
Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
Iridex Reports Second Quarter 2025 Financial Results
Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.